- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00543946
Single Ascending Dose of GAP-134 as a 24-hour IV Infusion in Healthy Japanese Males
Ascending Single Dose Study of The Safety, Tolerability, Pharmacokinetics, of GAP-134 Administered Intravenously as a 24-Hour Infusion to Healthy Japanese Male Subjects
Study Overview
Detailed Description
Atrial Fibrillation (AF) is the most commonly occurring sustained arrhythmia in clinical practice. AF is a serious disorder associated with an increased risk of stroke, morbidity and mortality, and the number of patients is estimated to double within the next 4 decades. The currently available antiarrhythmic drugs have limited efficacy and are associated with serious side effects of which potentially lethal ventricular proarrhythmias are one of the major concerns. Thus, there is a large unmet clinical need for efficacious and safe antiarrhythmic drugs for the treatment of AF.
The classical orientation of antiarrhythmic therapy has been to modulate cardiac ion channels (sodium, potassium or calcium) or the autonomic nervous system. However, numerous experimental and clinical studies have suggested that cardiac conduction slowing and impaired gap junction intercellular communication (GJIC) are important in the pathogenesis of cardiac arrhythmias, including AF. General conduction slowing or the presence of small islands of intra-atrial conduction block resulting from a decreased gap junction conductance, altered gap junction expression and heterogeneous spatial distribution of gap junctions may provide turning points for the multiple waves, and thereby promote re-entry of impulses. In recognition of this, several authors have proposed gap junction modulation as a potential new target in the treatment of AF. GAP-134 is an antiarrhythmic dipeptide that has demonstrated in vitro and in vivo efficacy in mouse and dog models of arrhythmia. GAP-134 has no apparent proarrhythmic activity or hemodynamic compromise and does not show any significant binding in a panel of >60 different receptors and ion channels. If determined to be safe and effective the indication sought for GAP-134 will be the prevention of post operative atrial fibrillation.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Tokyo
-
Shinagawa-Ku, Tokyo, Japan, 141-0001
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria
- Healthy Japanese men age 20-45.
- BMI within 17.6 to 26.4 kg/m2 and body weight greater than or equal to 45 kg.
- Nonsmoker or smoker of fewer than 10 cigarettes per day as determined by history. Must be able to abstain from smoking within 48 hours before study day 1 until the end of the inpatient confinement period.
Exclusion Criteria
- Any significant cardiovascular, hepatic, renal, respiratory, gastrointestinal, endocrine, immunologic, dermatologic, hematologic, neurologic, or psychiatric disease.
- Any surgical or medical condition that may interfere with the absorption, distribution, metabolism, or excretion of the test article (e.g., resection of liver, kidney, gallbladder, or gastrointestinal tract).
- Acute disease state.
- Any history of clinically important cardiac arrhythmias. Family history of long QT syndrome, Torsades de Pointes or unexpected cardiac death.
- Any clinically important deviation from normal limits in physical examination, vital signs, 12-lead electrocardiograms (ECGs), or clinical laboratory test results. Creatinine levels must be less than or equal to the upper limit of normal at screening.
- Demonstration of a positive orthostatic test at screening. The definition of a positive test is a greater than or equal to 20 mm Hg decrease in systolic blood pressure, greater than or equal to 10 mm Hg decrease in diastolic blood pressure, or a greater than or equal to 30 bpm increase in pulse rate, after standing for 3 minutes.
- Positive serologic findings for human immunodeficiency virus (HIV) antigen and antibodies, hepatitis B surface antigen (HbsAg), and/or hepatitis C virus (HCV) antibodies.
- Positive findings of urine drug screen.
- History of any clinically important drug allergy or adverse drug reaction (e.g., relapsing dermatitis, drug hypersensitivity, drug allergy, hypersensitivity to ingredient in the test articles or angioedemas)
- Use of any investigational drug within 90 days before study day 1 or prescription drug within 30 days before study day 1.
- Consumption of any caffeine-containing products.
- Consumption of grapefruit or grapefruit-containing products within 72 hours before study day 1 until the end of the inpatient confinement period.
- Use of any over-the-counter drugs, including herbal supplements (except for the occasional use of vitamins less than or equal to 100% of the recommended daily allowance), within 14 days before study day 1.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: Single
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The primary objective is to assess the safety and tolerability of ascending, single IV doses of GAP-134 as 24-hour continuous infusions and as a single bolus injection in healthy Japanese male subjects.
Time Frame: 6 months
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The secondary objective is to provide the initial PK profiles of ascending single IV doses (24 hour and 1-minute) of GAP-134 taken under fasting conditions in healthy Japanese male subjects.
Time Frame: 6 months
|
6 months
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 3205K2-1002
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Arrhythmia
-
Medical University of LodzNot yet recruitingCardiac Arrhythmia | Supraventricular ArrhythmiaPoland
-
SanofiCompletedVentricular Arrhythmia | Arrhythmia ProphylaxisNetherlands, Spain, Belgium, Japan, Finland, Chile, Australia, United States, Argentina, Canada, Czech Republic, Denmark, France, Germany, Hungary, Israel, Italy, Mexico, Norway, Poland, Portugal, Russian Federation, Slovakia, South Africa and more
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedHeart Diseases | Cardiovascular Diseases | Heart Failure | Arrhythmia | Heart Failure, Congestive | Sinus Arrhythmia
-
Ceryx Medical LtdCardiff and Vale University Health BoardNot yet recruitingHeart Failure With Reduced Ejection FractionUnited Kingdom
-
University of Wisconsin, MadisonNational Heart, Lung, and Blood Institute (NHLBI)Recruiting
-
Myant Medical Corp.Partners in Advanced Cardiac EvaluationCompleted
-
New York Institute of TechnologyCompleted
-
Atrial Fibrillation NetworkDaiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company; Preventicus GmbH; Corsano... and other collaboratorsCompletedAtrial ArrhythmiaGermany, Poland, Spain
-
Population Health Research InstituteBoston Scientific CorporationCompleted
-
MicroPort CRMCompletedAtrial ArrhythmiaUnited States, Germany, Spain, Denmark, Switzerland, France, Belgium, Australia, Japan, Italy, Canada, Netherlands
Clinical Trials on GAP-134
-
Wyeth is now a wholly owned subsidiary of PfizerCompleted
-
Wyeth is now a wholly owned subsidiary of PfizerCompletedHealthy SubjectsUnited States
-
Cantonal Hospital of St. GallenCompletedVentral Hernia | Recurrent Ventral HerniaSwitzerland
-
Charite University, Berlin, GermanyUnknownAcute Myeloid Leukemia | Myelodysplastic SyndromeGermany
-
Charite University, Berlin, GermanyUnknown
-
Agalimmune Ltd.CompletedSuperficial, Palpable, Unresectable/Metastatic Solid TumourUnited States, Israel, United Kingdom
-
Rubius TherapeuticsTerminated
-
Postgraduate Institute of Dental Sciences RohtakRecruiting
-
Assiut UniversityNot yet recruitingAssess the Relation Between Glycemic Gab and Adverse Clinical Outcomes in Diabetic Patients Who Hospitalized With Heart Failure
-
Virginia Commonwealth UniversityCenters for Disease Control and PreventionRecruiting